2026-05-07 · 2026-05 / week-1

Rising Dragon Is Pricing a Jammed Redemption Door

Rising Dragon Is Pricing a Jammed Redemption Door

Summary: Rising Dragon Acquisition trades far below its last reported trust value, but the discount is not clean cash. The market is pricing the public shares as if the redemption door is either operationally jammed or too ambiguous to underwrite. That is the mispricing: a possible trust claim is trading like stranded post-vote SPAC equity.

Opportunity Ranking

Rank Idea Discovery Lane Why It May Be Best Now Evidence Freshness Catalyst Window Asymmetry Main Reason to Reject
1 Rising Dragon public shares below stale trust value SPAC redemption / process dislocation RDAC traded at $7.92 while the 2025 10-K showed 4.201655 million redeemable shares at a $10.56 redemption value as of December 31, 2025. The April 28 PRE 14A creates a May 28 meeting and a May 26 redemption-process deadline, but the mechanics are tangled by the earlier HZJL business-combination vote. RDAC finance snapshot checked May 7, 2026, 11:48:30 UTC; PRE 14A filed April 28, 2026; 2025 10-K filed April 2, 2026. May 26, 2026 redemption deadline for the extension meeting; May 28, 2026 extraordinary general meeting; May 15 and July 15 deadline path. If redemption is available and processed, the stale trust reference is roughly 33% above the quote. If the right is not actually available to a new buyer, the discount is a warning, not a gift. Current quote pages conflict, the proxy is preliminary, and eligibility depends on settlement plus broker mechanics.
2 Esperion cash deal plus non-transferable CVR Biotech merger / CVR optionality ESPR traded at $3.15 against $3.16 cash plus a non-tradeable CVR tied to up to $100 million of aggregate net-sales milestones. The market is assigning little visible value to the CVR, but deal risk and non-transferability consume part of the edge. ESPR finance snapshot checked May 7, 2026, 11:00:03 UTC; ARCHIMED agreement announced May 1, 2026; SEC deal communication filed May 1, 2026. Stockholder and regulatory approvals; expected closing in 2026; 2027 bempedoic acid milestone and ENBUMYST milestone through 2030. The CVR may be underpriced, but the current common spread is only one cent below cash. Better CVR math requires sales modeling that is slower than today's event window, and the common price is already near cash.
3 XOMA cash deal plus litigation CVR premium Royalty-company merger / litigation CVR XOMA traded at $41.60 versus $39.00 cash plus a non-transferable CVR tied to 75% of net proceeds from certain litigation. The market is already paying about $2.60 over the cash component. XOMA finance snapshot checked May 7, 2026, 00:15:00 UTC; Ligand and XOMA agreement announced April 27, 2026. Stockholder vote, regulatory approvals, litigation monetization path. If the litigation recovery is real, the premium can be justified. The market is not giving the CVR away; the trade needs litigation diligence beyond this run's evidence.

Selected opportunity: Rising Dragon Acquisition Corp. (NASDAQ: RDAC) public shares.

Why this one now: The spread is too wide to treat as a normal SPAC arb quote, and the documents are too tangled to treat as a simple bargain. That is the edge. The right question is whether the May 28 extension meeting reopens a cash redemption path for the public shares that still trade.

What should surprise the reader: The cheapness is not hidden in valuation. It is hidden in process. A $7.92 quote against a stale $10.56 trust reference can be either a roughly one-third gross spread or a warning that the tradable line item is no longer the same asset as the trust claim.

Why This Is the Best Opportunity Right Now

Rising Dragon is a small SPAC tied to a proposed business combination with HZJL Cayman Limited. The common stock is not a clean operating-company bet. It is a corporate-action instrument with a live deadline, a preliminary proxy, prior redemption elections, extension financing, and uncertain quote quality.

The latest finance feed showed RDAC at $7.92 at 11:48:30 UTC on May 7, 2026. The 2025 annual report showed 4.201655 million ordinary shares subject to possible redemption at a redemption value of $10.56 as of December 31, 2025. That old trust mark is not the final May 2026 redemption value, but it is a hard enough reference point to make the screen price abnormal.

The April 28 PRE 14A adds the live event. Rising Dragon scheduled an extraordinary general meeting for May 28, 2026, to extend the combination period and amend the trust agreement. Public shareholders who want to redeem in connection with that meeting must follow the proxy process before 5:00 p.m. Eastern time on May 26, 2026. If the charter and trust amendments pass, the SPAC can extend from July 15, 2026 to October 15, 2027 through monthly deposits equal to the lesser of $100,000 or $0.033 per remaining public share.

This is the strongest current opportunity because it forces a precise answer. Either the public share still carries a usable redemption right into the May 28 meeting, or the quote is correctly discounting a busted process. The article is not useful because it says RDAC is cheap. It is useful because it tells the reader what must be verified before the cheapness counts.

What Should Surprise the Reader

Most SPAC redemption spreads are small because the asset is well understood. RDAC is different. The discount is large because the instrument is not well understood.

The proxy language is doing two jobs at once. It preserves a path for shareholders that already elected redemption in connection with the HZJL business-combination meeting, and it describes a new redemption process for the extension meeting. That creates an odd asset boundary. A holder must know whether the shares being bought today are eligible for the May 28 redemption process, whether settlement occurs before the broker's internal deadline, and whether the broker can deliver the shares correctly.

The surprise is that the best trade may be no trade unless the operational chain is provable. This is not a view on HZJL's business quality. It is a view on whether a public share below a filed trust reference still converts into cash.

The Setup

Rising Dragon completed its SPAC IPO in 2024 and later entered a business-combination agreement with HZJL Cayman Limited. The transaction path has already been stretched. In December 2025, shareholders approved an extension, and the 2025 annual report states that 1.548345 million shares were redeemed at approximately $10.55 per share at that meeting.

The remaining trust reference is visible. The same annual report showed 4.201655 million redeemable shares at $10.56 as of December 31, 2025. Since then, Rising Dragon has used sponsor and HZJL-related promissory notes to fund monthly extensions, including April 2026 notes whose proceeds were deposited into the trust account to extend the deadline to May 15, 2026.

The April 28 preliminary proxy is the current map. It asks shareholders to approve a charter amendment and a trust agreement amendment. If approved, Rising Dragon can extend the completion window well beyond July 15, 2026. If not approved, the company still describes a limited path to extend from May 15 to July 15 by making $100,000 monthly deposits. If it ultimately fails to complete a business combination by the applicable termination date, the proxy says it will redeem 100% of outstanding public shares, subject to law and claims.

The market is not trading this like a near-cash asset. It is trading it like a process-risk asset.

The Market Price

RDAC traded at $7.92 in the finance snapshot at 11:48:30 UTC on May 7, 2026. StockAnalysis' RDAC history page showed an $8.28 close on May 5, 2026, which supports the point that recent public quote pages place the common materially below the last reported trust value. The quote data is not perfect. Some public pages around thin SPAC names lag or conflict, and that uncertainty is part of the underwriting problem.

The stale trust reference is $10.56 as of December 31, 2025. Against $7.92, that is a $2.64 gap, or 33.3% before fees, settlement risk, taxes, potential trust deductions, and the real chance that a buyer cannot use the redemption window.

The spread is therefore not a yield. It is a question:

Item Level / Term Timestamp Why It Matters
RDAC finance-feed price $7.92 May 7, 2026, 11:48:30 UTC Current market level used for spread math.
RDAC StockAnalysis close $8.28 May 5, 2026 Independent quote-history support that the screen price recently sat far below trust.
Redeemable-share value in annual report $10.56 December 31, 2025 10-K Stale but primary-source trust reference.
Gross gap to stale trust mark $2.64, or 33.3% Desk calculation from $7.92 to $10.56 Too wide to ignore, too operational to treat as clean.
Extension-meeting redemption deadline 5:00 p.m. Eastern, May 26, 2026 April 28, 2026 PRE 14A The actual process deadline, before the meeting.
Extraordinary general meeting 10:00 a.m. Eastern, May 28, 2026 April 28, 2026 PRE 14A Vote date for charter and trust amendments.
Potential extension path Up to October 15, 2027 April 28, 2026 PRE 14A If approved, the SPAC can keep the deal path alive with monthly deposits.

The current price may be wrong. It may also be telling the truth about a cash right that is harder to own than it looks.

The Positioning

The best positioning evidence is mechanical.

SPAC arbitrage holders usually do not leave a one-third trust spread lying around unless something is off. In RDAC, several things can be off at once: a prior business-combination vote, earlier redemption elections, a preliminary extension proxy, an extremely thin remaining public float, conflicting quote pages, and the possibility that larger arbitrage desks cannot size the remaining line item.

That does not mean the market is efficient. It means the market may be demanding a process discount. A buyer of the public common has to answer four questions before treating the share as a cash claim:

  1. Is the share being bought the redeemable public ordinary share, not a right, warrant, unit, or post-corporate-action rump instrument?
  2. Will the trade settle in time for the broker's internal redemption deadline?
  3. Will the broker accept and process the redemption instruction for a share bought after the voting record date?
  4. Will the extension meeting actually create or preserve the cash election described in the preliminary proxy?

Missing data: I do not have live beneficial-owner concentration, DTCC position data, broker-specific cutoffs, or a definitive proxy with a final redemption value. The supported claim is narrower. The documents show a possible cash path, while the screen price says the market does not trust that path.

The Catalyst

The catalyst path is dated.

First, the preliminary proxy must become an operational corporate action. The meeting is scheduled for May 28, but the useful deadline is earlier. A holder seeking redemption has to complete the required procedure before 5:00 p.m. Eastern on May 26, and a broker may impose an earlier internal cutoff.

Second, shareholders vote on the charter and trust amendments. If approved, Rising Dragon can keep the HZJL transaction window open beyond July 15, 2026 through monthly extension deposits. If not approved, the company still describes a shorter extension path to July 15, but the long extension path fails.

Third, the HZJL business combination either proceeds, stalls, or breaks. If it proceeds, proper redemption process should matter more than the long-term HZJL equity story. If it stalls into liquidation, public-share cash recovery can still matter, but the timing and claim path change.

The closing mechanism is not a press release. It is a completed corporate-action instruction.

The Gap

The market appears to be pricing RDAC as a stranded, low-liquidity post-vote SPAC line item. The alternative interpretation is that the May 28 extension vote reopens or preserves a redemption door for public shares, making the $7.92 quote too low relative to a trust value last reported at $10.56.

Both interpretations can be true for different holders. A properly positioned holder with settled shares and a functioning broker process may own a cash claim. A late buyer with the wrong security, a stale quote, or a broker that will not process the election owns something else.

That is why the setup is asymmetric but not simple. The payoff is not driven by whether HZJL is a good company. It is driven by whether RDAC common is still a redeemable security before May 26.

The Payoff Map

One possible expression is RDAC public ordinary shares only after confirming the exact share line, settlement timing, broker redemption deadline, and eligibility for a share bought after the record date. The appropriate alternative expression may be no trade. Rights or warrants are not substitutes for this thesis because they do not carry the same cash redemption claim.

The top case is a clean redemption or liquidation path near the trust value, plus modest extension deposits and interest. The base case is redemption near the stale $10.56 reference after process verification. The bottom case is not that the trust value disappears. It is that the buyer never owned a usable cash right, misses the deadline, faces a broker refusal, or becomes exposed to HZJL equity or an illiquid market exit.

Price Target and Probability Map

Scenario Probability Target / Level Return / Payoff Time Horizon Conditions Required Evidence Quality
Top Case 30% $10.70 cash-equivalent recovery +35.1% versus $7.92 Late May to Q3 2026 Final proxy confirms redemption mechanics, broker processes the election, extension deposits and interest keep the cash value above the stale $10.56 mark, and the trust claim pays without unusual deductions. Medium
Base Case 45% $10.56 stale trust reference +33.3% versus $7.92 Late May to Q3 2026 The public share remains eligible for the May 28 redemption process, shares settle before the real broker deadline, and the stale annual-report trust value remains a reasonable proxy. Medium
Bottom Case 25% $5.50 market-exit / stranded-equity value -30.6% versus $7.92 Immediate to Q4 2026 A buyer cannot redeem, the quote represents an ineligible rump line, broker instructions fail, settlement misses the cutoff, or the position becomes post-close HZJL equity exposure. Low
Invalidation / Stop Condition n/a No verified redemption workflow before purchase No-trade / thesis break Immediate If the broker cannot confirm security eligibility, internal deadline, settlement, and redemption process, the trust spread is not underwritable. High

Probability-weighted expected value: Scenario-weighted target is $9.26, or +16.9% versus $7.92. This EV is process-weighted, not valuation-weighted. If redemption eligibility cannot be verified before trade entry, the EV should be treated as unavailable.

Current market price / level: RDAC $7.92 in the finance feed at May 7, 2026, 11:48:30 UTC. StockAnalysis showed an $8.28 close on May 5, 2026.

Timestamp: Research checked May 7, 2026, 19:35-20:35 Asia/Ho_Chi_Minh time.

Primary instrument: RDAC public ordinary shares only if eligible for redemption.

Alternative expressions considered: RDAC rights, RDAC warrants, units, post-close HZJL equity exposure, ESPR common for cash-plus-CVR, XOMA common for cash-plus-litigation-CVR, and no trade.

Confidence: Medium-low. The documents show the possible cash path. The quote and process ambiguity are precisely the risk.

What Could Go Wrong

The strongest counterparty argument is that the quote is not wrong. It may be correctly pricing an instrument that only looks like a redeemable SPAC share from a distance. If the traded line is effectively a thin, post-vote rump with no usable redemption election for a new buyer, $7.92 may be a rational discount to uncertain HZJL equity and stale process rights.

The second argument is operational. A holder can be right on the document and wrong in the account. Broker cutoffs often precede legal deadlines. A share bought after the May 1 voting record date may create confusion even if redemption rights normally attach to shares rather than votes. Thin settlement, corporate-action coding, and mistaken symbol selection can turn a theoretical trust spread into equity exposure.

The third argument is timing. The trust value cited here is the December 31, 2025 annual-report value, not a final May 2026 redemption value. Taxes, permitted withdrawals, claims, final extension deposits, and the exact count of remaining public shares can move the final number. The quote pages also conflict around thin SPAC securities, so the current price needs a live broker quote before any conclusion is actionable.

None of these objections kills the idea. They define it. RDAC is attractive only if the buyer can collapse the process uncertainty before the market closes the discount.

What Would Prove This Wrong

The thesis fails immediately if the definitive proxy, transfer agent, or broker confirms that shares bought now cannot be redeemed at the May 28 meeting. It also fails if the broker's internal deadline has already passed, if settlement cannot complete before the deadline, or if the security line being quoted is not the redeemable public ordinary share.

It also fails economically if RDAC reprices near $10.40-$10.60 before the process is verified. The spread is large now. It is not worth underwriting once it becomes a few cents with unresolved mechanics.

The hidden assumption is that the market is over-discounting operational ambiguity. If the market is instead seeing a real break in redemption eligibility, the cheap price is information, not opportunity.

Risk Audit

Strongest counterargument: The market may be right because the tradable RDAC line is not a straightforward trust claim for a new buyer.

Most fragile assumption: A buyer can still redeem the public shares in connection with the May 28 extension meeting after confirming broker and settlement mechanics.

What the market may already know: SPAC arbitrage desks may know the deadline, the record-date issue, the transfer-agent treatment, or the remaining-float problem better than public quote pages reveal.

What could make the trade lose money even if the thesis is directionally right: The holder buys too late, misses settlement, receives a broker refusal, selects the wrong security, or has to exit in a thin market before the redemption election is accepted.

Liquidity / execution risks: RDAC appears thin and quote quality is uneven. A large order can move the price. Limit-order discipline is mandatory for any process-driven expression.

Leverage risks: Leverage is a poor fit. A legal right can still fail operationally, and a one-day missed deadline can convert a cash-spread thesis into equity risk.

Information reliability risks: The proxy is preliminary, the final redemption value is not yet known, and public quote pages conflict. The 10-K trust value is primary-source data, but stale.

Invalidation trigger: No verified redemption instruction path, no definitive proxy confirmation, broker cutoff before settlement, or final documents that remove the cash election for current public-share buyers.

Publish / revise / reject recommendation: Publish as a process-driven event note with medium-low confidence, not as a clean cash-arbitrage call.

Bottom Line

Rising Dragon is not cheap in the ordinary way. It is cheap because the market does not trust the door between the public share and the trust account. At $7.92 against a stale $10.56 redemption reference, RDAC offers the appearance of a large cash spread. The trade exists only if that appearance survives a broker, settlement, transfer-agent, and final-proxy check before May 26. Until then, the right posture is conditional: verify the door before pricing the room behind it.

Sources